Maynard Um
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Neutral Rating on 4D Molecular Therapeutics (FDMT)
-
-
-
-
-
-
-
RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) PT Lowered to $40 at Jefferies
-
-
-
-
-
-
-
BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) PT Lowered to $40 at BMO Capital
-
-
-
-
-
431,644 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

